Last $7.72 USD
Change Today +0.3175 / 4.29%
Volume 199.5K
SCLN On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 3:59 PM 01/29/15 All times are local (Market data is delayed by at least 15 minutes).

sciclone pharmaceuticals inc (SCLN) Snapshot

Open
$7.41
Previous Close
$7.40
Day High
$7.72
Day Low
$7.34
52 Week High
12/19/14 - $9.14
52 Week Low
04/15/14 - $4.24
Market Cap
391.8M
Average Volume 10 Days
290.6K
EPS TTM
$0.45
Shares Outstanding
50.8M
EX-Date
--
P/E TM
17.2x
Dividend
--
Dividend Yield
--
Current Stock Chart for SCICLONE PHARMACEUTICALS INC (SCLN)

sciclone pharmaceuticals inc (SCLN) Related Bloomberg News

View More Bloomberg News

sciclone pharmaceuticals inc (SCLN) Related Businessweek News

No Related Businessweek News Found

sciclone pharmaceuticals inc (SCLN) Details

SciClone Pharmaceuticals, Inc., a specialty pharmaceutical company, provides therapies for the treatment of oncology, infectious diseases, and cardiovascular disorders primarily in the People’s Republic of China. Its lead product is ZADAXIN, which is used for the treatment of hepatitis B and hepatitis C viruses, and certain cancers, as well as for use as a vaccine adjuvant, and as a chemotherapy adjuvant for cancer patients with weakened immune systems. ZADAXIN has approval in approximately 30 countries, which include China, the Pacific Rim, Latin America, Eastern Europe, and the Middle East regions. The company markets and sells ZADAXIN through distribution arrangements, local importers, and distributors. It also markets approximately 10 partnered products in China, including Aggrastat, an interventional cardiology product. The company holds license, promotion, distribution, or marketing agreements with various parties for products, including DC Bead, Abstral, Loramyc, and ondansetron RapidFilm. SciClone Pharmaceuticals, Inc. was founded in 1989 and is headquartered in Foster City, California.

570 Employees
Last Reported Date: 03/17/14
Founded in 1989

sciclone pharmaceuticals inc (SCLN) Top Compensated Officers

Chief Executive Officer, President, Executive...
Total Annual Compensation: $550.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $160.4K
Chief Executive Officer of China Operations
Total Annual Compensation: $347.8K
Vice President of Finance and Chief Financial...
Total Annual Compensation: $279.4K
Vice President of Internal Audit
Total Annual Compensation: $273.5K
Compensation as of Fiscal Year 2013.

sciclone pharmaceuticals inc (SCLN) Key Developments

SciClone Pharmaceuticals, Inc. Reconfirms Earnings Guidance for the Year 2014; Provides Sales Revenue Guidance for the Year 2015

SciClone Pharmaceuticals, Inc. reconfirmed earnings guidance for the year 2014 and provided sales revenue guidance for the year 2015. For the year 2014, the company reconfirmed expected sales revenue of $130 million to $135 million, representing an approximate 30% increase of its core business revenue over 2013. The company reconfirmed non-GAAP EPS of $0.64 to $0.68, as a result of reduced marketing and general and administrative expenses. For the year 2015, the company anticipates sales revenue of $153 million to $158 million, representing an approximately 17% increase over 2014.

SciClone Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015

SciClone Pharmaceuticals, Inc. Presents at 7th annual Biotech Showcase Conference 2015, Jan-12-2015 . Venue: Parc 55 Wyndham San, Francisco - Union Square, San Francisco, CA 94102, United States.

SciClone Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 01:20 PM

SciClone Pharmaceuticals, Inc. Presents at Boston Biotech Conferences LLC's The East Meets West CEO conference, Jan-10-2015 01:20 PM. Venue: Four Seasons Hotel, 757 Market St, San Francisco, CA 94103. Speakers: Andrew Wong.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
SCLN:US $7.72 USD +0.315

SCLN Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Lannett Co Inc $50.06 USD +0.38
Momenta Pharmaceuticals Inc $10.97 USD +0.31
Pernix Therapeutics Holdings Inc $8.51 USD +0.02
Sagent Pharmaceuticals Inc $26.55 USD +0.32
Sarepta Therapeutics Inc $12.29 USD +0.29
View Industry Companies
 

Industry Analysis

SCLN

Industry Average

Valuation SCLN Industry Range
Price/Earnings 18.1x
Price/Sales 3.0x
Price/Book 2.4x
Price/Cash Flow 17.3x
TEV/Sales 2.2x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SCICLONE PHARMACEUTICALS INC, please visit www.sciclone.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.